Zhejiang Conba Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" for ZY13 extract and tablets issued by the National Medical Products Administration. The notice numbers are 2024LP2333 and 2024LP2334, with the dosage form being tablets. The application indication is age-related macular degeneration caused by kidney yin deficiency and hyperactivity of liver fire. The registration classification is traditional chinese medicine 1.2 new drugs.
康恩贝：ZY13提取物及片获药物临床试验批准
Zhejiang Conba Pharmaceutical: ZY13 extract and tablets have obtained approval for clinical trials of drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated